Overview

Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Status:
Completed

Trial end date:
2019-02-27

Target enrollment:

Participant gender:

Summary

Participants with agitation secondary to dementia of the Alzheimer's type. The diagnosis of probable Alzheimer's disease (AD) will be based on the "2011 Diagnostic Guidelines for Alzheimer's Disease" issued by the National Institute on Aging (NIA)-Alzheimer's Association (AA) workgroups.

Phase:

Phase 3

Details

Lead Sponsor:

Avanir Pharmaceuticals

Treatments:

Dextromethorphan
Quinidine
Quinidine gluconate